Central Nervous System (CNS) Therapeutics Market to Reach USD 152.4 Billion by 2034

Pune, India, November 2025 - The global Central Nervous System (CNS) Therapeutics Market is set for strong expansion, projected to grow from USD 93.7 billion in 2024 to USD 152.4 billion by 2034, registering a CAGR of 4.9%, according to the latest report by Exactitude Consultancy. Growth is primarily driven by increasing cases of neurological disorders, wider adoption of biologics, and rapid progress in CNS-targeted therapeutics.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/51211

Key Takeaways
• Market Size (2024): USD 93.7 Billion
• Forecast (2034): USD 152.4 Billion
• CAGR: 4.9% (2024-2034)
• Top Segments: Neurodegenerative diseases, psychiatric disorders, pain management
• Top Players: Biogen, Pfizer, Novartis, Eli Lilly, Roche, Teva, Johnson & Johnson
• Key Trend: Shift toward precision neurology & CNS biologics

Market Story
Neurological conditions-including Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, migraine, and depression-continue to represent a growing global healthcare burden. Rising geriatric population, increased awareness, and improved diagnostic capabilities have significantly expanded demand for CNS therapeutics.

Innovations in targeted drug delivery (BBB-penetrating molecules), gene therapies, monoclonal antibodies, and neuroprotective agents are shaping the next decade of CNS treatment. Pharmaceutical companies are shifting focus from symptomatic treatment to disease-modifying therapies, especially in neurodegenerative disorders.

Growing investments by biotech firms, expanding clinical pipelines, and favorable regulatory approvals from FDA and EMA are also catalyzing rapid market expansion.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/51211/central-nervou-s-system-therapeutics-market

Market Segmentation
By Disease Type
• Neurodegenerative Disorders
• Psychiatric Disorders
• Infectious CNS Diseases
• Pain Management
• Others (brain tumors, trauma-related disorders)
By Drug Class
• Analgesics
• Antidepressants
• Antipsychotics
• Antiepileptics
• Anesthetics
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Geography
• North America (largest share driven by R&D investments)
• Europe
• Asia Pacific (fastest-growing region)
• South America
• Middle East & Africa

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=51211

Recent Industry Developments
• 2024: Biogen and Eisai expanded Alzheimer's therapy collaborations for next-generation amyloid-targeting agents.
• 2023: FDA approved new treatments for rare epileptic disorders and resistant depression.
• 2023-2024: Roche, Novartis, and Teva increased investments in biologics and gene therapy platforms for neurodegenerative diseases.
• 2024: Multiple AI-driven neurology drug discovery programs launched by leading biotech firms.

Expert Quote
"The CNS therapeutics market is undergoing a transformation toward precision neurology, with targeted biologics and next-gen drug delivery technologies leading future growth," said Irfan Tamboli, Business Development Executive at Exactitude Consultancy. "With increasing global neurological burden, companies investing in innovation will benefit from long-term expansion."

Market Drivers
• Rising prevalence of Alzheimer's, Parkinson's, and psychiatric disorders
• Advancements in BBB-penetrating formulations
• Growing demand for biologics & gene-based therapies
• Favorable regulatory approvals
• Increased healthcare spending worldwide

Forecast Outlook (2024-2034)
The market is expected to maintain steady growth as pharma innovators prioritize neurological R&D pipelines. Asia-Pacific will record the highest CAGR due to rapidly improving healthcare infrastructure and pharmaceutical expansion into emerging economies.

This report is also available in the following languages : Japanese (中枢神経系治療薬市場), Korean (중추신경계 치료제 시장), Chinese (美国中枢神经系统治疗市场), French (Marché américain des thérapies du système nerveux central), German (Markt für Therapeutika für das zentrale Nervensystem in den USA), and Italian (Mercato terapeutico del sistema nervoso centrale degli Stati Uniti), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/51211

Our More Reports:

Cryogenic Freezers Market
https://exactitudeconsultancy.com/reports/50194/cryogenic-freezers-market

Soft Skin Adhesives Market
https://exactitudeconsultancy.com/reports/50197/soft-skin-adhesives-market

Artificial Intelligence Ai In Medical Imaging Market
https://exactitudeconsultancy.com/reports/50199/artificial-intelligence-ai-in-medical-imaging-market

Laboratory Automation Market
https://exactitudeconsultancy.com/reports/50201/laboratory-automation-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.